| Name | Title | Contact Details |
|---|
CeQur is dedicated to helping people with type 2 diabetes manage their disease by developing and commercializing simple drug delivery devices that can be easily integrated into daily life. The company`s lead product, PaQ, is a wearable insulin delivery device that delivers both basal and bolus insulin for 3 days at a time. Its simple, discreet design enables people to easily experience the benefits of intensive insulin therapy, while remaining free from the burdens of daily insulin injections. CeQur SA was established in January 2008 as a spinout from Danfoss A/S, a global Danish industrial products group that developed the initial concept of the CeQur technology. CeQur recently completed a clinical study evaluating PaQ among people with type 2 diabetes with positive results. The company has advanced the technology to a commercial product obtaining a CE mark for PaQ in 2012. CeQur is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.
Bioness offers award-winning medical devices designed to benefit people with stroke, Multiple Sclerosis, traumatic brain injury, Cerebral Palsy, and spinal cord injury. These products use electrical stimulation to help people regain mobility and
PetVivo, Inc is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. PetVivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo`s strategy is to in-license proprietary products from human medical device companies specifically for use in pets. PetVivo, Inc, Gel-Del Technologies, Inc. and CosmetaLife a Corporation are all wholly-owned subsidiaries of PetVivo Holdings, Inc.
Co-View Capital is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.